GoldBamboo.com - Knowledge is strong medicine
  

Patupilone Activity in Advanced/Metastatic Hepatocelluar Carcinoma - Article


  Not Signed In - Sign In / Register




General Topics A-Z

Adrenocortical Carcinoma

Adrenocortical Carcinoma, Childhood

Clinical Trial: Patupilone Activity in Advanced/Metastatic Hepatocelluar Carcinoma

This study is not yet open for patient recruitment.
Verified by Novartis January 2006

Sponsored by: Novartis
Information provided by: Novartis
ClinicalTrials.gov Identifier: NCT00273312

Purpose

This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatoculluar carcinoma based on tumor response using modified RECIST criteria.
Condition Intervention Phase
Hepatocellular Carcinoma
  Drug: patupilone
 Phase II

MedlinePlus related topics:  Liver Cancer

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title: An Open-Label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC)

Further study details as provided by Novartis:

Study start: January 2006

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion criteria:

- Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable lesion without any systemic single agent or combination chemotherapy. Previous local therapy is allowed.

Exclusion criteria:

Additional protocol-defined inclusion/exclusion criteria apply.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00273312


California
      City of Hope National Medical Center, Duarte,  California,  91010,  United States
Laura Alvarado  626-301-8111    lalvarado@coh.org 
Y. Yen, Dr.,  Principal Investigator

      SUSCF, San Francisco,  California,  94115,  United States
Benny Luu  415-353-7284    bluu@medicine.ucsf.edu 
A. Venook, Dr,  Principal Investigator

Connecticut
      St. Fancis Hospital and Med Ctr,, Hartford,  Connecticut,  06105,  United States
Eileen P. Levine  860-714-7701    elevine@stfranciscare.org 
J. Sporn, Dr.,  Principal Investigator

New Mexico
      Univ of New Mexico Cancer Center, Albuquerque,  New Mexico,  87131,  United States
Valerie Parks  505-272-0898    vparks@salud.unm.edu 
Y . Patt, Dr.,  Principal Investigator

Pennsylvania
      Univ of Pittsburgh Medical Center, Pittsburgh,  Pennsylvania,  15213,  United States
Alida Schleyer  412-692-2007    schleyerah@upmc.edu 
B Carr, Dr,  Principal Investigator

Study chairs or principal investigators

Novartis,  Study Chair,  Novartis   

More Information

Study ID Numbers:  CEPO906A2213
Last Updated:  January 6, 2006
Record first received:  January 4, 2006
ClinicalTrials.gov Identifier:  NCT00273312
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10


Source: ClinicalTrials.gov
Cache Date: January 11, 2006


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Adrenocortical Carcinoma.

October 8, 2008


Page Updated: October 3, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Massachusetts Law | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.